IL18 and lung carcinoma: In summary, our study identified two axes in the immune cell-inflammatory factor-lung cancer pathway, namely HLA DR on CD33dim HLA DR+ CD11b+ - Interleukin-18 - lung cancer and HLA DR on CD33dim HLA DR+ CD11b+ - Interleukin-13 - lung cancer.